• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高分辨率、高加速 MRI T2 映射作为一种特征性肾肿瘤亚型和分级的工具。

High-resolution and highly accelerated MRI T2 mapping as a tool to characterise renal tumour subtypes and grades.

机构信息

Department of Radiology, University of Cambridge, Cambridge, CB2 0QQ, UK.

The Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China.

出版信息

Eur Radiol Exp. 2024 Jul 10;8(1):76. doi: 10.1186/s41747-024-00476-8.

DOI:10.1186/s41747-024-00476-8
PMID:38981998
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11233479/
Abstract

BACKGROUND

Clinical imaging tools to probe aggressiveness of renal masses are lacking, and T2-weighted imaging as an integral part of magnetic resonance imaging protocol only provides qualitative information. We developed high-resolution and accelerated T2 mapping methods based on echo merging and using k-t undersampling and reduced flip angles (TEMPURA) and tested their potential to quantify differences between renal tumour subtypes and grades.

METHODS

Twenty-four patients with treatment-naïve renal tumours were imaged: seven renal oncocytomas (RO); one eosinophilic/oncocytic renal cell carcinoma; two chromophobe RCCs (chRCC); three papillary RCCs (pRCC); and twelve clear cell RCCs (ccRCC). Median, kurtosis, and skewness of T2 were quantified in tumours and in the normal-adjacent kidney cortex and were compared across renal tumour subtypes and between ccRCC grades.

RESULTS

High-resolution TEMPURA depicted the tumour structure at improved resolution compared to conventional T2-weighted imaging. The lowest median T2 values were present in pRCC (high-resolution, 51 ms; accelerated, 45 ms), which was significantly lower than RO (high-resolution; accelerated, p = 0.012) and ccRCC (high-resolution, p = 0.019; accelerated, p = 0.008). ROs showed the lowest kurtosis (high-resolution, 3.4; accelerated, 4.0), suggestive of low intratumoural heterogeneity. Lower T2 values were observed in higher compared to lower grade ccRCCs (grades 2, 3 and 4 on high-resolution, 209 ms, 151 ms, and 106 ms; on accelerated, 172 ms, 160 ms, and 102 ms, respectively), with accelerated TEMPURA showing statistical significance in comparison (p = 0.037).

CONCLUSIONS

Both high-resolution and accelerated TEMPURA showed marked potential to quantify differences across renal tumour subtypes and between ccRCC grades.

TRIAL REGISTRATION

ClinicalTrials.gov, NCT03741426 . Registered on 13 November 2018.

RELEVANCE STATEMENT

The newly developed T mapping methods have improved resolution, shorter acquisition times, and promising quantifiable readouts to characterise incidental renal masses.

摘要

背景

目前缺乏用于探测肾肿块侵袭性的临床成像工具,磁共振成像(MRI)方案中的 T2 加权成像仅提供定性信息。我们开发了基于回波合并的高分辨率和加速 T2 映射方法,利用 k-t 欠采样和减少翻转角(TEMPURA),并测试了其量化肾肿瘤亚型和分级之间差异的潜力。

方法

对 24 例未经治疗的肾肿瘤患者进行了成像:7 例肾嗜酸细胞瘤(RO);1 例嗜酸细胞/嗜酸细胞瘤肾细胞癌;2 例嫌色细胞肾细胞癌(chRCC);3 例乳头状肾细胞癌(pRCC);12 例透明细胞肾细胞癌(ccRCC)。在肿瘤和正常邻近肾皮质中定量了 T2 的中位数、峰度和偏度,并比较了肾肿瘤亚型之间和 ccRCC 分级之间的差异。

结果

与常规 T2 加权成像相比,高分辨率 TEMPURA 可更清晰地描绘肿瘤结构。pRCC 的 T2 值最低(高分辨率,51ms;加速,45ms),明显低于 RO(高分辨率,加速,p=0.012)和 ccRCC(高分辨率,加速,p=0.019)。RO 表现出最低的峰度(高分辨率,3.4;加速,4.0),提示肿瘤内异质性较低。与低级别 ccRCC 相比,高级别 ccRCC 的 T2 值更低(高分辨率,2 级、3 级和 4 级分别为 209ms、151ms 和 106ms;加速,2 级、3 级和 4 级分别为 172ms、160ms 和 102ms),加速 TEMPURA 在比较中具有统计学意义(p=0.037)。

结论

高分辨率和加速 TEMPURA 均显示出在肾肿瘤亚型和 ccRCC 分级之间定量差异的巨大潜力。

试验注册

ClinicalTrials.gov,NCT03741426。2018 年 11 月 13 日注册。

相关性声明

新开发的 T 映射方法具有提高分辨率、缩短采集时间的优点,有望提供可量化的读数来对偶然发现的肾肿块进行特征描述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6450/11233479/ac9e2ada838e/41747_2024_476_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6450/11233479/2dc1f9c1ebd9/41747_2024_476_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6450/11233479/66d16f241545/41747_2024_476_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6450/11233479/5aa7b2992f71/41747_2024_476_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6450/11233479/8fcabb99e272/41747_2024_476_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6450/11233479/ac9e2ada838e/41747_2024_476_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6450/11233479/2dc1f9c1ebd9/41747_2024_476_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6450/11233479/66d16f241545/41747_2024_476_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6450/11233479/5aa7b2992f71/41747_2024_476_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6450/11233479/8fcabb99e272/41747_2024_476_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6450/11233479/ac9e2ada838e/41747_2024_476_Fig5_HTML.jpg

相似文献

1
High-resolution and highly accelerated MRI T2 mapping as a tool to characterise renal tumour subtypes and grades.高分辨率、高加速 MRI T2 映射作为一种特征性肾肿瘤亚型和分级的工具。
Eur Radiol Exp. 2024 Jul 10;8(1):76. doi: 10.1186/s41747-024-00476-8.
2
Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.利用对比增强MDCT和FSE T2加权MRI图像对透明细胞和乳头状肾细胞癌进行肿瘤分级评估:放射学与病理学相关性研究
Radiol Med. 2021 Sep;126(9):1139-1148. doi: 10.1007/s11547-021-01350-y. Epub 2021 Jun 7.
3
Fast and High-Resolution T Mapping Based on Echo Merging Plus k-t Undersampling with Reduced Refocusing Flip Angles (TEMPURA) as Methods for Human Renal MRI.基于回波合并和 k-t 欠采样的快速高分辨率 T 映射与减少重聚焦翻转角(TEMPURA)作为人类肾脏 MRI 的方法。
Magn Reson Med. 2024 Sep;92(3):1138-1148. doi: 10.1002/mrm.30115. Epub 2024 May 10.
4
Application of diffusion kurtosis tensor MR imaging in characterization of renal cell carcinomas with different pathological types and grades.扩散峰度张量磁共振成像在不同病理类型和分级的肾细胞癌中的应用。
Cancer Imaging. 2021 Mar 16;21(1):30. doi: 10.1186/s40644-021-00394-7.
5
Evaluation of renal cell carcinoma histological subtype and fuhrman grade using F-fluorodeoxyglucose-positron emission tomography/computed tomography.利用 F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描评估肾细胞癌的组织学亚型和 Fuhrman 分级。
Eur Radiol. 2017 Nov;27(11):4866-4873. doi: 10.1007/s00330-017-4875-z. Epub 2017 May 18.
6
Comparison of cortico-medullary phase contrast-enhanced MDCT and T2-weighted MR imaging in the histological subtype differentiation of renal cell carcinoma: radiology-pathology correlation.皮质髓质期对比增强MDCT与T2加权MRI成像在肾细胞癌组织学亚型鉴别中的比较:放射学与病理学相关性
Pol J Radiol. 2021 Oct 15;86:e583-e593. doi: 10.5114/pjr.2021.111013. eCollection 2021.
7
Routinely performed multiparametric magnetic resonance imaging helps to differentiate common subtypes of renal tumours.常规进行的多参数磁共振成像有助于区分肾肿瘤的常见亚型。
Eur Radiol. 2014 May;24(5):1068-80. doi: 10.1007/s00330-014-3107-z. Epub 2014 Feb 21.
8
Grading Clear Cell Renal Cell Carcinoma Grade Using Diffusion Relaxation Correlated MR Spectroscopic Imaging.应用扩散弛豫相关磁共振波谱成像对透明细胞肾细胞癌分级。
J Magn Reson Imaging. 2024 Feb;59(2):699-710. doi: 10.1002/jmri.28777. Epub 2023 May 20.
9
Differentiation of renal cell carcinoma subtypes through MRI-based radiomics analysis.基于 MRI 的影像组学分析对肾细胞癌亚型的鉴别诊断。
Eur Radiol. 2020 Oct;30(10):5738-5747. doi: 10.1007/s00330-020-06896-5. Epub 2020 May 4.
10
Renal cell carcinoma: applicability of the apparent coefficient of the diffusion-weighted estimated by MRI for improving their differential diagnosis, histologic subtyping, and differentiation grade.肾细胞癌:MRI估计的扩散加权表观系数在改善其鉴别诊断、组织学亚型分类及分化程度判断方面的适用性
Int Urol Nephrol. 2017 Feb;49(2):215-224. doi: 10.1007/s11255-016-1460-3. Epub 2016 Nov 16.

引用本文的文献

1
Histopathological and immunohistochemical characteristics of adult renal tumors: a five-year retrospective study in Mureş County, Romania.罗马尼亚穆列什县成人肾脏肿瘤的组织病理学和免疫组织化学特征:一项为期五年的回顾性研究。
Rom J Morphol Embryol. 2024 Jul-Sep;65(3):457-465. doi: 10.47162/RJME.65.3.08.
2
Feasibility and Reproducibility of T2 Mapping Compared with Diffusion-Weighted Imaging in Solid Renal Masses.T2 映射与扩散加权成像在实性肾肿块中的可行性及可重复性比较
Bioengineering (Basel). 2024 Sep 7;11(9):901. doi: 10.3390/bioengineering11090901.

本文引用的文献

1
Fast and High-Resolution T Mapping Based on Echo Merging Plus k-t Undersampling with Reduced Refocusing Flip Angles (TEMPURA) as Methods for Human Renal MRI.基于回波合并和 k-t 欠采样的快速高分辨率 T 映射与减少重聚焦翻转角(TEMPURA)作为人类肾脏 MRI 的方法。
Magn Reson Med. 2024 Sep;92(3):1138-1148. doi: 10.1002/mrm.30115. Epub 2024 May 10.
2
The multispeciality approach to the management of localised kidney cancer.多学科方法治疗局限性肾癌。
Lancet. 2022 Aug 13;400(10351):523-534. doi: 10.1016/S0140-6736(22)01059-5. Epub 2022 Jul 19.
3
The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
2022 年世界卫生组织泌尿系统和男性生殖器官肿瘤分类 - 第 A 部分:肾脏、阴茎和睾丸肿瘤。
Eur Urol. 2022 Nov;82(5):458-468. doi: 10.1016/j.eururo.2022.06.016. Epub 2022 Jul 16.
4
T2 mapping in myocardial disease: a comprehensive review.心肌疾病的 T2 映射:全面综述。
J Cardiovasc Magn Reson. 2022 Jun 6;24(1):33. doi: 10.1186/s12968-022-00866-0.
5
Multicenter Evaluation of Multiparametric MRI Clear Cell Likelihood Scores in Solid Indeterminate Small Renal Masses.多中心评估在实性不确定小肾肿块中多参数 MRI 透明细胞可能性评分
Radiology. 2022 Jun;303(3):590-599. doi: 10.1148/radiol.211680. Epub 2022 Mar 15.
6
How We Do It: Managing the Indeterminate Renal Mass with the MRI Clear Cell Likelihood Score.方法:采用 MRI 透明细胞似然评分管理不确定的肾脏肿块。
Radiology. 2022 Feb;302(2):256-269. doi: 10.1148/radiol.210034. Epub 2021 Dec 14.
7
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.WIRE 研究:一项 II 期、多臂、多中心、非随机机会窗临床试验平台,采用贝叶斯自适应设计,用于探索可手术肾细胞癌新型治疗策略的作用机制——研究方案。
BMC Cancer. 2021 Nov 18;21(1):1238. doi: 10.1186/s12885-021-08965-4.
8
Progress Against Cancer Mortality 50 Years After Passage of the National Cancer Act.《国家癌症法案》通过 50 年后癌症死亡率的进展。
JAMA Oncol. 2022 Jan 1;8(1):156-159. doi: 10.1001/jamaoncol.2021.5668.
9
Objective response rate assessment in oncology: Current situation and future expectations.肿瘤学中的客观缓解率评估:现状与未来期望。
World J Clin Oncol. 2020 Feb 24;11(2):53-73. doi: 10.5306/wjco.v11.i2.53.
10
iRECIST: how to do it.iRECIST:如何实施。
Cancer Imaging. 2020 Jan 3;20(1):2. doi: 10.1186/s40644-019-0281-x.